Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 4M | 4M |
| Gross Profit | 4M | 4M | 3M | 3M | 4M |
| Operating Income | -2M | -4M | -5M | -3M | -1M |
| EBITDA | -2M | 49K | -4M | 2M | -1M |
| Net Income | -4M | -5M | -9M | -15M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0002
+33.33% today
1Y Change
-99.26%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stemtech Corporation (STEK) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +2.7%, EPS growth of +51.2%, a dividend yield of 0.0%. What stands out right now is revenue +2.7%, EPS +51.2%, free cash flow +70.5% with operating margin -48.6% and ROIC 43.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines STEK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STEK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STEK Max Drawdown
-99.69%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STEK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.4M
+1.5% YoY
FY Net Income
-$1.7M
+88.7% YoY
Free Cash Flow
-$278.3K
+85.5% YoY
Revenue Growth
+2.7%
EPS Growth
+51.2%
Gross Margin
80.4%
Net Margin
-79.2%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 4M | 4M |
| Gross Profit | 4M | 4M | 3M | 3M | 4M |
| Operating Income | -2M | -4M | -5M | -3M | -1M |
| EBITDA | -2M | 49K | -4M | 2M | -1M |
| Net Income | -4M | -5M | -9M | -15M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 255K | 114K | 132K | 828K | 133K |
| Total Assets | 4M | 4M | 4M | 6M | 5M |
| Total Liabilities | 9M | 6M | 7M | 10M | 4M |
| Shareholder Equity | -4M | -2M | -2M | -3M | 2M |
| Total Debt | 4M | 4M | 1M | 1M | 889K |
| Net Debt | 4M | 4M | 1M | 622K | 756K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
267K
+86.1% YoY
Capital Expenditures
12K
Free Cash Flow
278K
+85.5% YoY
Key ratios
Gross Margin
80.4%
Operating Margin
-48.6%
Net Margin
-79.2%
ROE
56.5%
Debt / Equity
-0.41x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.